Trevi Therapeutics
TRVI
36 hedge funds and large institutions have $80.4M invested in Trevi Therapeutics in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 4 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
0.3% more ownership
Funds ownership: 72.07% → 72.38% (+0.3%)
4% less capital invested
Capital invested by funds: $83.3M → $80.4M (-$2.94M)
3% less funds holding
Funds holding: 37 → 36 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
98% less call options, than puts
Call options by funds: $2K | Put options by funds: $88K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$794K |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$268K |
| 3 |
TCOT
Trust Company of Toledo
Holland,
Ohio
|
+$188K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$136K |
| 5 |
TC
Tejara Capital
London,
United Kingdom
|
+$91.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$294K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$272K |
| 3 |
Millennium Management
New York
|
-$222K |
| 4 |
Renaissance Technologies
New York
|
-$182K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$45.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $51.2K | +$62.6K | +27,666 | New |
|
|
B
27
Bailard
Foster City,
California
| $39.2K | – | – | – |
|
28
Bank of New York Mellon
New York
| $26.1K | – | – | – |
|
29
Two Sigma Investments
New York
| $23.9K | -$35.6K | -15,725 | -55% |
|
30
Charles Schwab
San Francisco,
California
| $23.2K | – | – | – |
|
31
Squarepoint
New York
| $21.2K | +$26K | +11,474 | New |
|
32
LPL Financial
San Diego,
California
| $18.5K | – | – | – |
|
33
UBS Group
Zurich,
Switzerland
| $14K | +$10.2K | +4,489 | +145% |
|
34
Morgan Stanley
New York
| $710 | -$124 | -55 | -13% |
|
35
Wells Fargo
San Francisco,
California
| $490 | +$9 | +4 | +2% |
|
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$294K | -152,300 | Closed |
|
|
VF
37
Virtu Financial
New York
| – | -$27K | -13,995 | Closed |
|
38
First Manhattan
New York
| – | -$965 | -500 | Closed |
|
39
Bank of America
Charlotte,
North Carolina
| – | -$178 | -92 | Closed |
|
TRVI Hedge Fund Activity: Q1 2023 in Review
36 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q1 2023, worth a combined $80.4M — down 3.5% from $83.3M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TRVI and 3 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 11 added.
The largest buyer was Opaleye Management, adding an estimated $794K. The largest seller was Bank of Montreal, exiting entirely with an estimated $294K sold.
- 36 institutional investors held Trevi Therapeutics (TRVI) as of Q1 2023, down from 37 in Q4 2022.
- Funds reported $80.4M of Trevi Therapeutics stock for Q1 2023, down 3.5% quarter-over-quarter.
- 3 funds opened new Trevi Therapeutics positions in Q1 2023 and 4 closed out, a net change of -1 holder.
- The largest Trevi Therapeutics buyer in Q1 2023 was Opaleye Management, an estimated $794K added.
- The largest Trevi Therapeutics seller in Q1 2023 was Bank of Montreal, an estimated $294K sold.
Based on aggregated 13F filings for Q1 2023.